October 24, 2006 –Cambrex sold its biobusinesses to Lonza Group AG for $460 million; Elan and Biogen Idec reported Tysabri maintained remission in Crohn’s disease patients for 2 years; InterMune said its two pulmonary fibrosis drugs worked better together; Peregrine completed enrollment of a Phase Ib test of its hepatitis C drug; Myriad Genetics will provide genetic testing for a pancreatic cancer trial; Nucryst said its nanocrystalline silver was effective against inflammation in preclinical tests; AstraZeneca received approval for a liquid formulation of its proton pump inhibitor, Nexium; and BioVex formally withdrew its IPO application, after failing to price last week. The Centient Biotech 200™ slipped 3 points lower to 3957, a loss of .09%. More details...
